| 1 |
35202484 | PharmVar GeneFocus: CYP3A5. | 2022 Feb 24 |
1 |
| 2 |
30501535 | Inhibition of CYP3A4 and CYP3A5 expression by scutellarin is not mediated via the regulation of hsa-miR-27a, 27b, 148a, 298 and 451a levels. | 2020 Nov |
1 |
| 3 |
31356678 | Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions. | 2020 Jan |
1 |
| 4 |
30517006 | CYP3A4/5 Activity Probed with Testosterone and Midazolam: Correlation between Two Substrates at the Microsomal and Enzyme Levels. | 2019 Jan 7 |
1 |
| 5 |
30981185 | Screening for CYP3A4 inhibition and induction coupled to parallel artificial membrane permeability assay (PAMPA) for prediction of botanical-drug interactions: The case of açaí and maca. | 2019 Jun |
1 |
| 6 |
28986606 | Effect of breviscapine on CYP3A metabolic activity in healthy volunteers. | 2018 Jan |
2 |
| 7 |
29719052 | Effect of single-walled carbon nanotubes on cytochrome P450 activity in human liver microsomes in vitro. | 2018 May |
1 |
| 8 |
30166405 | Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers. | 2018 Nov |
1 |
| 9 |
28344076 | Inhibition of human CYP3A4 and CYP3A5 enzymes by gomisin C and gomisin G, two lignan analogs derived from Schisandra chinensis. | 2017 Jun |
1 |
| 10 |
28533324 | CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism. | 2017 Aug |
1 |
| 11 |
28944677 | Multiplex and Label-Free Relative Quantification Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-MS. | 2017 Nov 3 |
1 |
| 12 |
26921388 | Biosynthesis of Fluorinated Analogs of Drugs Using Human Cytochrome P450 Enzymes Followed by Deoxyfluorination and Quantitative Nuclear Magnetic Resonance Spectroscopy to Improve Metabolic Stability. | 2016 May |
1 |
| 13 |
27511886 | Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. | 2016 Oct |
2 |
| 14 |
27666601 | Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole. | 2016 Dec 1 |
1 |
| 15 |
25287072 | The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. | 2015 Apr |
1 |
| 16 |
25590378 | The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells. | 2015 Mar 2 |
2 |
| 17 |
24214410 | CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients. | 2014 Feb |
3 |
| 18 |
24696691 | Clinical pharmacology of midazolam in neonates and children: effect of disease-a review. | 2014 |
2 |
| 19 |
24737844 | Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide). | 2014 Jul |
1 |
| 20 |
23324807 | Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. | 2013 Mar |
3 |
| 21 |
24024898 | Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. | 2013 Sep |
2 |
| 22 |
22511346 | Interaction of lapatinib with cytochrome P450 3A5. | 2012 Jul |
1 |
| 23 |
22673786 | Pharmacogenetics in perioperative medicine. | 2012 Aug |
1 |
| 24 |
20954901 | CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity. | 2011 Jan |
2 |
| 25 |
21266595 | Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation. | 2011 May |
9 |
| 26 |
20814160 | Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans. | 2010 |
1 |
| 27 |
21281268 | Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole. | 2010 Apr |
1 |
| 28 |
18948377 | Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5. | 2009 Jan |
1 |
| 29 |
19506580 | Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. | 2009 Oct |
2 |
| 30 |
17954524 | The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. | 2008 Jan |
1 |
| 31 |
17554244 | Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. | 2007 Oct |
1 |
| 32 |
17786417 | Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation. | 2007 Dec |
1 |
| 33 |
18001057 | Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. | 2007 Dec |
1 |
| 34 |
16430309 | Significance of the minor cytochrome P450 3A isoforms. | 2006 |
1 |
| 35 |
15900284 | Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. | 2005 May |
1 |
| 36 |
16243813 | Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. | 2005 Oct 15 |
2 |
| 37 |
15114431 | Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. | 2004 Jun |
1 |
| 38 |
15179407 | CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. | 2004 Jun |
1 |
| 39 |
15289787 | Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. | 2004 Aug |
4 |
| 40 |
15383492 | Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. | 2004 Dec |
1 |
| 41 |
15499178 | CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. | 2004 Apr |
4 |
| 42 |
12814972 | In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. | 2003 Jul |
2 |
| 43 |
14515058 | Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. | 2003 Oct |
1 |
| 44 |
14625349 | A significant drug-metabolizing role for CYP3A5? | 2003 Dec |
6 |
| 45 |
14637191 | Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. | 2003 Dec 15 |
1 |
| 46 |
12065767 | Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. | 2002 Jul |
2 |
| 47 |
12202670 | Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. | 2002 Sep 1 |
1 |
| 48 |
12406645 | Genetic contribution to variable human CYP3A-mediated metabolism. | 2002 Nov 18 |
1 |
| 49 |
12433824 | Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. | 2002 Dec |
1 |
| 50 |
10898111 | Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. | 2000 Jul |
1 |